Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,546.00    82.00 (3.33%)
Bid:
2,544.00
Ask:
2,548.00
Spread: 4.00 (0.157%)
Market Cap: £8.17b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

Today 07:00

RNS Number : 2843J
Bunzl PLC
23 June 2026
 

23 June 2026

 BUNZL PRE-CLOSE STATEMENT

2026 outlook upgraded; bolt-on acquisition completed in Australia

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the six months ending 30 June 2026.

Group revenue over the first half of 2026 is expected to grow by around 4% at constant exchange rates, with underlying revenue growth of around 3%. We expect growth to be supported by inflation across certain categories in the second quarter, with product-cost increases driven by geopolitical events, and we are also seeing encouraging volume growth. Volume growth is expected to be driven by North America, with good growth in our Distribution business. Our Distribution business continues to see operational progress as a result of actions taken, with encouraging volume growth across customers and supported by the additional benefit from new business wins that were achieved towards the end of last year. Over the first half, acquisitions, net of disposals, are expected to contribute growth of around 1% to the Group, and currency is expected to have a relatively neutral impact on revenue at actual exchange rates.

The Group expects good year-on-year growth in adjusted operating profit over the first half at constant exchange rates. Operating margin is expected to be up modestly year-on-year due to the net impact of inflation in the second quarter, much of which is expected to be temporary in nature, and the annualisation of Nisbets synergies.

While we remain mindful of continuing macroeconomic and geopolitical uncertainties, we are encouraged by our performance and upgrade our 2026 guidance. The Group now expects revenue growth at constant exchange rates to be driven by modest underlying revenue growth, supported by some inflation, alongside a small benefit from acquisitions. Our operating margin guidance is unchanged and we continue to expect it to be slightly down year-on-year.

In April, Bunzl completed the acquisition of Scientifix Group, an Australian distributor of critical products and services to the Life Sciences and Biotechnology sectors that will expand the category offering of our existing business. In the 12 months to June 2026, the business is expected to generate revenue of AUD 18 million (c.£9 million).

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

"Bunzl is expecting to deliver an improved performance in the first half, with continued underlying growth and robust profitability, demonstrating the resilience and agility of our business model. Furthermore, I am pleased that our North America Distribution business has achieved the good operational progress we had expected, with the business' responsiveness, agility and high service levels largely restored. We continue to expect 2026 to be a foundation for future profit growth.

I am also delighted to welcome Scientifix into the Group, a company that is an excellent strategic fit with our existing healthcare business in Australia, and further enhances our exposure to this attractive value-added sector. Our acquisition pipeline remains active and we continue to expect 2026 to be an improved year for acquisitions. We continue to see significant opportunities to further consolidate our fragmented global markets, and remain confident in our ability to generate long-term compounding growth and value creation for all of our stakeholders."

Conference call

There will be a live analyst and investor conference call and Q&A session from 8.00am (BST) today, hosted by Richard Howes (Chief Financial Officer). A replay will be available later in the day.

Dial-in number: + 44 20 3936 2999 / Access code: 534897

Enquiries:

Bunzl plc (Tel: +44 (0)20 7725 5000)

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations and Communications

Teneo (Tel: +44 (0)20 7353 4200)

Martin Robinson

Kate Somerville

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBRGDLXGDDGLD
Date   Source Headline
2nd Aug 20213:40 pmRNSTotal Voting Rights
14th Jul 20214:11 pmRNSDirector/PDMR Shareholding
7th Jul 20219:30 amRNSDirector/PDMR Shareholding
1st Jul 202112:30 pmRNSTotal Voting Rights
24th Jun 20217:00 amRNSTrading Statement
23rd Jun 20218:00 amRNSAdditional Listing
3rd Jun 20211:00 pmRNSDirector/PDMR Shareholding
1st Jun 20211:00 pmRNSTotal Voting Rights
26th May 20219:30 amRNSDirector Declaration
26th May 20218:00 amRNSAdditional Listing
18th May 20217:00 amRNSAcquisition
6th May 202110:40 amRNSDirector/PDMR Shareholding
5th May 20211:15 pmRNSDirector/PDMR Shareholding
5th May 20211:01 pmRNSDirector/PDMR Shareholding
4th May 202110:50 amRNSTotal Voting Rights
4th May 20219:25 amRNSBlock listing Interim Review
22nd Apr 20214:40 pmRNSDirector/PDMR Shareholding
21st Apr 20214:16 pmRNSResult of AGM
21st Apr 20217:00 amRNSTrading Statement
14th Apr 202111:45 amRNSDirector/PDMR Shareholding
12th Apr 20218:43 amRNSDirector/PDMR Shareholding
12th Apr 20218:24 amRNSDirector/PDMR Shareholding
7th Apr 20213:24 pmRNSDirector/PDMR Shareholding
1st Apr 202111:44 amRNSTotal Voting Rights
31st Mar 20215:34 pmRNSDirector/PDMR Shareholding
22nd Mar 20214:30 pmRNSDirector Declaration
17th Mar 20214:27 pmRNSAnnual Financial Report
8th Mar 20215:53 pmRNSDirector/PDMR Shareholding
5th Mar 20211:10 pmRNSDirector/PDMR Shareholding
4th Mar 20215:33 pmRNSDirector/PDMR Shareholding
3rd Mar 202110:00 amRNSDirector Declaration
1st Mar 20212:00 pmRNSTotal Voting Rights
1st Mar 20211:00 pmRNSDirector/PDMR Shareholding
1st Mar 20211:00 pmRNSDividend Declaration
1st Mar 20217:00 amRNSFinal Results
1st Mar 20217:00 amRNSAcquisition
1st Feb 202110:00 amRNSTotal Voting Rights
20th Jan 20217:00 amRNSDirector Declaration
6th Jan 20214:00 pmRNSDirector/PDMR Shareholding
4th Jan 202111:50 amRNSTotal Voting Rights
22nd Dec 20207:00 amRNSDirectorate Change
16th Dec 20208:00 amRNSAdditional Listing
16th Dec 20207:00 amRNSTrading Statement
9th Dec 20208:00 amRNSAdditional Listing
3rd Dec 20209:27 amRNSDirector/PDMR Shareholding
2nd Dec 20208:00 amRNSAdditional Listing
1st Dec 202011:57 amRNSTotal Voting Rights
20th Nov 202012:30 pmRNSDirector Declaration
9th Nov 20207:00 amRNSAcquisition
3rd Nov 20205:18 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.